Literature DB >> 2824044

The EGF receptor: structure, regulation and potential role in malignancy.

D M Thompson1, G N Gill.   

Abstract

Retroviral onc genes are derived from cellular proto-oncogenes that may function in normal cellular growth control. The epidermal growth factor (EGF) receptor is the proto-oncogene of erbB; both possess intrinsic protein tyrosine kinase activity, a property shared by several retroviral onc genes. The EGF receptor is a transmembrane glycoprotein with an external EGF binding domain and a cytoplasmic region that is homologous with other tyrosine kinases. erbB lacks the EGF binding and carboxyl terminal regions, which are thought to be important in regulation. The EGF receptor is regulated by several mechanisms: stimulation by ligand binding and self-phosphorylation, inhibition by heterologous phosphorylation and downregulation by ligand. EGF binding stimulates several early events, including phosphatidylinositol (PI) turnover in A431 cells. A PI kinase activity copurifies with the EGF receptor and some other tyrosine kinases, but this is a contaminant as it can be separated from the EGF receptor. Although the role of proto-onc genes in human malignancy is incompletely defined, increased numbers of EGF receptors are present in several types of human tumours. Overexpression of EGF receptors, as occurs in human epidermoid carcinoma A431 cells, can augment cell growth because of increased formation of active ligand:receptor complexes. Gene amplification is the mechanism underlying overexpression of EGF receptors in A431 cells and in some glioblastoma multiforme tumours.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2824044

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  18 in total

1.  Overexpression of the epidermal growth factor receptor gene in a human carcinoma cell line, derived from a brain metastasis.

Authors:  E Helseth; A Dalen; G Unsgaard; R Vik; A Helseth
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

Review 2.  Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.

Authors:  S Morin-Ben Abdallah; V Hirsh
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

3.  Epidermal growth factor receptor defects in leprechaunism. A multiple growth factor-resistant syndrome.

Authors:  S S Reddy; C R Kahn
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

4.  The effects of type beta transforming growth factor on proliferation and epidermal growth factor receptor expression in a human glioblastoma cell line.

Authors:  E Helseth; G Unsgaard; A Dalen; R Vik
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130

5.  Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy.

Authors:  Sherly Quiles; Kevin P Raisch; Leisa L Sanford; James A Bonner; Ahmad Safavy
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

6.  Regulation of surface expression of high-affinity receptors for epidermal growth factor (EGF) in hepatocytes by hormones, differentiating agents, and phorbol ester.

Authors:  I P Gladhaug; M Refsnes; T Christoffersen
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

7.  The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase.

Authors:  M F Lin; G M Clinton
Journal:  Mol Cell Biol       Date:  1988-12       Impact factor: 4.272

8.  Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.

Authors:  Angeles Alvarez Secord; John A Blessing; Deborah K Armstrong; William H Rodgers; Zoe Miner; Mack N Barnes; George Lewandowski; Robert S Mannel
Journal:  Gynecol Oncol       Date:  2008-01-14       Impact factor: 5.482

Review 9.  Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.

Authors:  David J Iberri; A Dimitrios Colevas
Journal:  Oncologist       Date:  2015-10-07

Review 10.  Genetic variation: effect on prostate cancer.

Authors:  Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi
Journal:  Biochim Biophys Acta       Date:  2014-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.